Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

New evidence compares micro-ultrasound and MRI fusion biopsy for detecting clinically significant prostate cancer. Find out ...

A ground-breaking prostate cancer treatment that aims to target tumours without as many side effects has showed promising ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

In patients with elevated PSA, the urinary MPS2 test had high accuracy for ruling out high-grade prostate cancer requiring biopsy. The urinary 18-gene MyProstateScore 2.0 (MPS2) test can detect ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...